Emergency Medicine Is (NOT) Dead

03/31/25 • 36 min

1 Listener

In this episode of 'Talking Shift,' the host welcomes Dr. Chris Doty, an important figure in emergency medicine, to discuss his journey and the current state of the specialty. Dr. Doty reflects on a crisis from two years ago where a significant number of emergency medicine residency spots went unmatched, but more recent data shows improvement. They explore changes in residency program requirements, particularly the potential shift from three-year to four-year programs, and the implications of such modifications. The conversation also touches on the impact of the pandemic on the perception and reality of working in emergency medicine, the financial pressures of medical education, and the trend towards shorter, more manageable training periods. Additionally, they discuss fellowships, emerging trends, and the critical issue of burnout, especially highlighted during the pandemic. Dr. Doty emphasizes the importance of choosing the right residency program and the vital need for systemic changes to support healthcare professionals better.

Previous Episode

$undefined - Refractory Hypoxemia$

Refractory Hypoxemia

In this inaugural episode of 'Talking Shift,' we dive deep into the complex world of managing refractory hypoxemia and ventilator settings with special guest Nick Ghionne, aka @PulmToilet. Explore strategies for optimizing ventilator parameters, understanding the role of driving pressure, effective use of PEEP, and the critical benefits of proning. We also discuss the nuanced use of adjuncts like nitric oxide and epoprostenol. Learn practical tips for real-life scenarios, ensuring better patient outcomes in critical care. Tune in to gain invaluable insights from two experts and elevate your critical care expertise!

Next Episode

Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage

In this episode, we break down the ANNEXA-I randomized trial, which looked at patients with factor Xa inhibitor-associated intracerebral hemorrhage. The study compared andexanet alfa, a targeted reversal agent, with usual care (mainly prothrombin complex concentrate).

The results? Andexanet showed better hemostatic control and more effectively reduced hematoma expansion (67% vs. 53.1%), with a 94.5% median drop in anti-factor Xa activity. But the benefit came with a trade-off—higher rates of thrombotic events, particularly ischemic stroke.

We dive into the clinical implications of these findings and what they mean for balancing bleeding control with thrombotic risk. Whether you're managing ICH cases or staying updated on anticoagulation reversal strategies, this one’s for you.